High Efficacy and Safety of Nanobody Based Anti-BCMA CAR-T Cell Therapy in Treating Patients with Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Zhang, Xian [1 ,2 ]
Wang, Lin [3 ]
Yang, Junfang [4 ,5 ]
Li, Jingjing [4 ,5 ]
Liu, Hongxing [4 ,5 ]
Li, Jianqiang [6 ]
Lu, Peihua [2 ,4 ]
机构：
[1] Beijing Lu Daopei Hosp, Beijing, Peoples R China
[2] Hebei Yanda Lu Daopei Hosp, Dept Hematol, Langfang, Peoples R China
[3] Hebei Senlang Biotechnol, Shijiazhuang, Hebei, Peoples R China
[4] Beijing Lu Daopei Inst Hematol, Beijing, Peoples R China
[5] Hebei Yanda Lu Daopei Hosp, Langfang, Peoples R China
[6] Hebei Senlang Biotechnol Co Ltd, Shijiazhuang, Hebei, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185271
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Anti-BCMA CAR-T cell immunotherapy for relapsed or refractory multiple myeloma
    Zhang, Xiaohui
    Ouyang, Chenxi
    Sun, Guofeng
    Liu, Hongfeng
    Qi, Junyuan
    Suo, Xiaohui
    [J]. EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (04)
  • [2] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    He, Shao-long
    Cheng, Yu-hang
    Wang, Di
    Xu, Meng-lei
    Que, Yi-mei
    Xu, Yan-jie
    Ma, Liang-ming
    Li, Chun-rui
    Zhou, Jian-feng
    [J]. CURRENT MEDICAL SCIENCE, 2021, 41 (03) : 474 - 481
  • [3] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    Shao-long He
    Yu-hang Cheng
    Di Wang
    Meng-lei Xu
    Yi-mei Que
    Yan-jie Xu
    Liang-ming Ma
    Chun-rui Li
    Jian-feng Zhou
    [J]. Current Medical Science, 2021, 41 : 474 - 481
  • [4] Developing a Novel Anti-Bcma CAR-T for Relapsed or Refractory Multiple Myeloma
    Yao, Xin
    Zhu, Shigui
    Huang, Jiaqi
    Qu, Xiaoyan
    Zhu, Judy
    Wei, Yutian
    Lan, Liping
    Lv, Xiaoteng
    Wu, Junfeng
    Wang, Rirfei
    Yang, Dingzhu
    Zheng, Chengxiao
    Zhao, DiJun
    Fan, Lei
    Huang, Fei
    Lu, Hua
    Zhang, Chaocan
    Chen, Cheng
    Li, Yanfeng
    Ren, Jiaqiang
    Zhang, Li
    Humphries, Michael
    Li, Jianyong
    Yao, Yihong
    [J]. BLOOD, 2019, 134
  • [5] Safety and Efficacy of Anti-Bcma CAR-T Cells for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Literature
    Khan, Israr
    Rafae, Abdul
    Javaid, Anum
    Ahmed, Zahoor
    Qadeer, Haifza Abeera
    Khan, Sana Irfan
    Dar, Abdul Jabbar
    Khurshid, Qasim
    Jaan, Ali
    Khalid, Farhan
    Aijaz, Zobia
    Hashmi, Mydah Sajid
    Malik, Mustafa Nadeem
    Anwer, Faiz
    [J]. BLOOD, 2020, 136
  • [6] Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
    Feng, Deming
    Sun, Jian
    [J]. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2020, 92 (02)
  • [7] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    [J]. CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
  • [8] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    [J]. Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [9] Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
    Deng, Haobin
    Liu, Meijing
    Yuan, Ting
    Zhang, Huan
    Cui, Rui
    Li, Jingyi
    Yuan, Jijun
    Wang, Xiaofang
    Wang, Yafei
    Deng, Qi
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [10] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    [J]. LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
12345